Corrigendum

Abdela, J. (2019). Current Advance in Thrombopoietin Receptor Agonists in the Management of Thrombocytopenia Associated With Chronic Liver Disease: Focus on Avatrombopag. Clinical Medicine Insights: Blood Disorders, 12, 1179545X19875105. DOI: 10.1177/1179545X19875105

In the above article, the following sentences have been published incorrectly. Below are the correct sentences:

1. In Introduction section, paragraph 1, sentence number 6: Prophylactic transfusion of platelets reduces the risk of bleeding in patients with CLD and platelet count <50 × 10⁹ /L that required to undergo invasive procedure.

2. In Overview of TPO-R Agonists That Received FDA Approval section, paragraph 1, sentence number 6: In addition, phase I/II study carried out on pediatric patients with CITP illustrated of 17 children who used romiplostim, 15 (88%) of them achieved platelet count of ⩾50 × 10⁹/L for 2 consecutive weeks whereas 5 children who used placebo did not show any improvement (P = .0008).

3. In Overview of TPO-R Agonists That Received FDA Approval section, paragraph 4, sentence number 5: Accordingly, in phase II/III of PETIT, 62% of children with ITP achieved platelet counts of ⩾50 × 10⁹/L from a baseline of <30 × 10⁹/L, whereas in phase-III trials of PETIT 2, 36% of children with 1-5 years, 42% of children with 6 to 11 years, and 39% of children with 12 to 17 years obtained the desired level of platelet counts of ⩾50 × 10⁹/L from the baseline which is <30 × 10⁹/L (Table 1).

4. In Table 1, under the column of “Clinical condition for which the drug is approved or under clinical trial”, in the row “PETIT” – CITP. Under the number of “participants involved in the study (received drug of interest or placebo)” in the row of “Cohort A” – last line 17 patients received 100mg loading dose/80mg

5. In Phase-III Study, paragraph 2, sentence number 6: The median platelet count by a visit in avatrombopag-treated patients was reliably higher than that of the placebo-treated group starting from day 8 (80.5 x10⁹ /L vs 8x10⁹/L) whereas the median platelet count for the placebo-treated group remained unaltered throughout the core study.